The 15-month study will test a biopolymer scaffold product, which was developed to treat patients with acute traumatic spinal cord injuries. Currently, no FDA-approved treatments exist or are in clinical trials for direct spinal cord intervention, according to the release.
More Articles on Devices:
Stryker Names William Jellison CFO
Biomet Gains Exclusive Distribution Rights to OPM OsteoFab Implants
13 Spine Devices Receive FDA 510(k) Clearance in March
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
